药品专利权的国际法保护

International Law Perspective on Pharmaceutical Patent Protection

药品专利权的国际法保护受到了许多发展中国家的挑战。在公民健康权与药品专利权之间,以巴西和印度为代表的发展中国家选择了偏向于公民健康权,而多数发达国家更注重对于药品专利权的保护,两者博弈无休止。世界知识产权保护组织需要在药品的专利保护和公民的健康权之间寻求一种平衡,这不仅仅是政府与医药公司对于药品的利润博弈,根本上说,更是发达国家与发展中国家的经济博弈。我国药品专利保护程度应当与我国经济开放及发展程度相匹配。一味地寻求专利保护而忽略了发展程度,法律保护往往难以落到实处,同时还可能造成公民健康隐患。因此,我国药品专利保护法在与国际法接轨的同时,应当在药品专利和公民健康之间寻求平衡。

It is a great challenge of pharmaceutical intellectual property rights protection for many developing countries.Most of them,such as Brazil and India,vote for the people s health needs instead of the pharmaceutical IP rights,while developed countries prefer the latter.The game is endless.The World IP Protection Organization would like to find a balance in the benefit battle between the governments and the medicine companies.Actually,it is more exact expression that it is an economic game between the developed countries and the developing countries.For China,the intensity of pharmaceutical IP rights protection should be match with the level of economic development.If the balance is broken and goes to the deviation of IP rights,laws will be just words on the paper,let alone the people s health.As a result,Chinese law rules should have been in accordance with the international laws,and at the same time,the balance between the pharmaceutical IP rights protection and people s health needs should be kept.